Article Figures & Tables
Figures
- Figure 1:
Predicted probabilities of cost-related nonadherence among Canadians by income level. Error bars indicate 95% confidence intervals. Income levels are based on annual household incomess: low = less than $20 000, low/medium = $20 000–$39 999, medium = $40 000–$59 999, medium/high = $60 000–$79 999, high = $ 80 000 or more.
Tables
- Table 1:
Characteristics and prevalence of cost-related nonadherence among respondents to the Canadian Community Health Survey in 2007
Characteristic Respondents with complete data, no. Respondents who received a prescription, no. Respondents who reported cost- related nonadherence, no. Weighted prevalence of cost-related nonadherence,* % (95% CI) Overall 7917 5732 540 9.6 (8.4–10.7) Province Atlantic provinces 1191 889 105 11.9 (8.9–14.9) Quebec 1542 1062 68 7.2 (4.5–9.8) Ontario 2629 1932 168 9.1 (7.2–11.0) Saskatchewan and Manitoba 947 686 71 8.9 (6.0–11.7) Alberta 777 565 40 7.6 (4.6–10.7) British Columbia 831 598 88 17.0 (12.6–21.4) Age, yr 12–34 2116 1295 135 9.4 (7.2–11.6) 35–44 1253 809 86 11.4 (8.2–14.7) 45–64 2813 2121 229 10.8 (8.7–12.9) ≥ 65 1735 1507 90 4.8 (3.6–6.0) Sex Female 4363 3453 358 10.7 (9.2–12.2) Male 3554 2279 182 8.2 (6.4–9.9) Health status Excellent or very good 4573 2993 207 6.9 (5.6–8.2) Good 2341 1820 173 10.4 (8.0–12.8) Fair or poor 1003 919 160 20.1 (15.7–24.4) Chronic conditions, no. 0 4687 2797 221 8.2 (6.7–9.7) 1 1880 1637 171 11.2 (8.7–13.7) ≥ 2 1350 1298 148 12.4 (9.8–15.1) Annual household income, $ < 20 000 948 764 136 20.5 (15.2–25.8) 20 000–39 999 1663 1270 143 13.7 (10.7–16.7) 40 000–59 999 1469 1054 102 10.5 (7.8–13.3) 60 000–79 999 1236 867 71 10.4 (7.1–13.6) ≥ 80 000 2601 1777 88 5.4 (3.9–6.9) Level of education Less than high school 1787 1228 100 7.3 (4.9–9.8) High school 1213 861 81 11.9 (8.1–15.6) Some postsecondary 516 376 48 12.8 (7.8–17.7) Postsecondary graduate 4401 3267 311 9.2 (7.8–10.6) Insurance coverage for prescription drugs Yes 6506 4840 337 6.8 (5.7–7.8) No 1411 892 203 26.5 (21.8–31.3) Note: CI = confidence interval.
↵* Percentages were calculated using number of respondents who reported receiving a prescription, weighted to represent the overall Canadian population.
- Table 2:
Factors associated with cost-related nonadherence among respondents to the Canadian Community Health Survey 2007 who reported having received one or more prescriptions for medication
Variable OR (95% CI) Province Atlantic provinces 1.21 (0.71–2.07) Quebec 1.26 (0.76–2.07) Ontario (reference) 1.00 Saskatchewan and Manitoba 1.08 (0.59–1.97) Alberta 1.19 (0.61–2.31) British Columbia 2.56 (1.49–4.42) Age, yr 12–34 4.70 (2.91–7.60) 35–44 5.57 (3.45–8.98) 45–64 3.74 (2.55–5.49) ≥ 65 (reference) 1.00 Sex Female 1.17 (0.86–1.59) Male (reference) 1.00 Health status Excellent or very good (reference) 1.00 Good 1.35 (0.95–1.93) Fair or poor 2.64 (1.77–3.94) Chronic conditions 0 (reference) 1.00 1 1.35 (0.92–1.98) ≥ 2 1.61 (1.07–2.43) Annual household income, $ < 20 000 3.29 (2.03–5.33) 20 000–39 999 2.47 (1.59–3.84) 40 000–59 999 1.84 (1.18–2.85) 60 000–79 999 1.87 (1.17–3.00) ≥ 80 000 (reference) 1.00 Level of education Less than high school 0.58 (0.33–1.04) High school (reference) 1.00 Some postsecondary 1.12 (0.61–2.05) Postsecondary graduate 0.99 (0.65–1.50) Insurance coverage for prescription drugs Yes (reference) 1.00 No 4.52 (3.29–6.20) Note: CI = confidence interval, OR = odds ratio.
In this issue
Article tools
Respond to this article
The effect of cost on adherence to prescription medications in Canada
Jump to section
Related Articles
Cited By...
- Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study
- Effect of free distribution of medicines on the process of care for adult patients with type 1 and type 2 diabetes and hypertension: post hoc analysis of randomised controlled trial findings
- Universal Drug Coverage and Socioeconomic Disparities in Health Care Costs Among Persons With Diabetes
- The mirage of universality: Canadas failure to act on social policy and health care
- Exploring the experiences of people in Ontario, Canada who have trouble affording medicines: a qualitative concept mapping study
- Compliance packaging: Be aware of the hidden cost
- Acceptability and feasibility of a national essential medicines list in Canada: a qualitative study of perceptions of decision-makers and policy stakeholders
- Prescription medication nonadherence associated with food insecurity: a population-based cross-sectional study
- Demographic characteristics and cost of treatment among oncology patients in a publicly funded system, the Ontario Trillium Drug Program: a retrospective cohort study
- Should national pharmacare apply a value-based insurance design?
- Impact of a household-level deductible on prescription drug use among lower-income adults: a quasi-experimental study
- Public prescription drug plan coverage for antiretrovirals and the potential cost to people living with HIV in Canada: a descriptive study
- Patterns of borrowing to finance out-of-pocket prescription drug costs in Canada: a descriptive analysis
- Improving the quality of health care in Canada
- The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey
- Testing and treatment for obstructive sleep apnea in Canada: funding models must change
- Social considerations of inflammatory bowel disease in Southern Israel
- Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge Medicines (CLEAN Meds) trial
- Impact of income-based deductibles on drug use and health care utilization among older adults
- Lacces aux medicaments par lhospitalisation
- Medication access via hospital admission
- Liste canadienne des medicaments essentiels: Potentiel et incertitudes
- Canadian list of essential medications: Potential and uncertainties
- Potential contribution of lifestyle and socioeconomic factors to healthy user bias in antihypertensives and lipid-lowering drugs
- The effects of catastrophic drug plan deductibles on older women's use of cardiovascular medicines: a retrospective cohort study
- Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada
- Development of a preliminary essential medicines list for Canada
- Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries
- Cost-related nonadherence to prescribed medicines among older Canadians in 2014: a cross-sectional analysis of a telephone survey
- Estimated cost of universal public coverage of prescription drugs in Canada
- Delivering on the promise of Medicare
- Concretiser les promesses du regime d'assurance-maladie
- Addressing cost-related barriers to prescription drug use in Canada
- Chronic Physical and Mental Health Conditions among Adults May Increase Vulnerability to Household Food Insecurity
- The road to competitive generic drug prices in Canada
- Universal Drug Coverage and Socioeconomic Disparities in Major Diabetes Outcomes
- Leadership on prescription drugs needed